Cytonet’s Liver Cell Therapy Trial for children with urea cycle disorders expands to Canada

Health Canada recently granted Cytonet approval to extend the SELICA (Safety and Efficacy of Liver Cell Application)-III clinical trial into Canada. This trial, which has been open in the U.S. since 2010, is designed to evaluate the safety and efficacy of liver cell therapy in infants to children up to five years of age with urea cycle disorders (UCD). Two centers in Canada will join the 12 medical centers in the U.S. taking part in the trial: the Alberta Children’s Hospital in Calgary and the Hospital for Sick Kids in Toronto. “Adding centers in Canada will help us achieve our goal of enrolling 20 children in the trial and more widely offers a much-needed new option for a very serious condition where the only current cure is liver transplantation,” says Dr. Wolfgang Rudinger, CEO and CSO of Cytonet Germany. For more information, please visit http://www.cytonetllc.com.